(Sponsored on behalf of BYND Cannasoft)
BYND Cannasoft Enterprise (NASDAQ: BCAN) (CSE: BYND) shares present a compelling value proposition at current prices. In fact, at $1.29, BCAN stock may be too good to ignore. Yes, that's a decidedly bullish sentiment. But considering that BCAN targets a niche opportunity within the global AI market, expected to reach $1.5 trillion by 2030, it's warranted. In fact, finding under-the-radar investment opportunities in the sector, like BCAN, may now provide the biggest bang for the investment buck, with the massive triple-digit percentage runs by some of the sector leaders, including Advanced Micro Devices (NASDAQ: AMD), NVIDIA (NASDAQ: NVDA), and Palantir (NASDAQ: PLTR), pricing them either at or above fair value.
But know this: choosing the right company matters, noting that gone are the days when a keyword in a company name, like CBD, could attract thousands of investors and generate millions in market cap. Make no mistake- thousands, potentially millions, of micro-cap investors learned an expensive lesson during that mad rush to CBD stocks. While many got financially burned, that era did help create a wiser investment mentality that appreciates substance over hype before investing hard-earned dollars. The lesson learned included finding companies that advance their mission with product, pipeline, and IP strength. While not providing full insulation from downside, that combination significantly mitigates risk. It also provides a checklist for what supports a reasoned investment consideration.
Having a compelling product, pipeline, and IP portfolio, BCAN checks the right boxes. Moreover, they are yet to be included in the substantial runs of other AI companies. However, that could change. And deservedly so, considering recent weakness resulting from a successful $2.6 million capital raise that puts BCAN in its best-ever position to expedite an ambitious 2023 agenda. It's not uncommon for shares to decline to complete a capital raise. But more often than not, the discount exposes opportunity based on the company emerging the transaction appreciably better positioned to capitalize on its business mission. BCAN is no exception.
Positioning To Monetize Niche AI-Empowered Opportunities
In fact, investors paid over double BCAN's current $1.29 price just two weeks ago. Not only that, BCAN held considerable support above the $3.00 level throughout all of June. So, why the decline? Because, like most micro-cap raising capital, BCAN sold shares at a discount during its recent underwritten public offering. More specifically, they sold them at $1.50, which, notably, is roughly 15% higher than current levels, with no warrants mentioned. In other words, investors, most likely accredited or institutional, appreciated the value at higher prices. Rightfully so, considering its strengthened position to tap into a sensual wellness product sales opportunity forecast to reach $62.32 billion by 2030.
But BCAN isn't presenting more of the same. Instead, they target revenue-generating potential from AI-empowered, interactive wearables and technology that can revolutionize the sector. Moreover, BCAN is doing more than seizing opportunities; it's building an IP portfolio that could keep the direct competitive landscape relatively thin. That's a value driver in and of itself. Moreover, considering that only about nine million shares trade in its public float, according to MarketWatch, the upside potential generated from expected milestones reached, especially concerning preserving its market share, could be considerable and accrue quickly.
That's not all. Insider interest is significant. According to Yahoo! Finance on 7/24/23, insiders own over 64% of the outstanding stock, which, in no uncertain terms, aligns management and insider interests with common shareholders. Better still, based on recent positive news on patent applications, it's unlikely those shares will be separated from them anytime soon. In other words, an already small float and tightly held shares could create a supply and demand imbalance that favors LONG side investors.
IP Portfolio Arsenal Protects Niche Interests
With milestones that can become catalysts, that dynamic is more than likely; it's probable. That includes value inherent to BCAN's recently filed Patent Cooperation Treaty (PCT) application for their EZ-G, a game-changing device utilizing AI and sensors to provide a more sensual user experience. A positive update on that application could unleash significant upside potential, noting it could be a first-to-market product in an emerging category.
Remember, early movers are generally the best rewarded for supporting higher valuations. Modeling for higher BCAN prices would be no exception, especially with the AI-powered adult products market already presenting multi-billion dollar revenue potential and, as significantly, BCAN positioning itself as a leading sector player with IP-protected competitive advantages over later entrants. While already impressive, BCAN's IP arsenal is getting more robust.
Earlier this year, the company announced that in addition to the US Provisional Patent Application, 63/297,009 filed, they filed a full-scale PCT application PCT/IL2023/050016. The PCT application is based on its prototype of the EZ-G device, which is currently under development. The applications cover its EZ-G device's monitoring and controlling aspects, with further claims priority from the US Provisional application covering device design and structure. The company believes that besides potentially treating annoying phenomena in the female reproductive system, the EZ-G device's technological advancements will provide other benefits to heighten the user experience.
Differences Are Advantages That Exploit Potential
Its product pipeline is certainly different; that's a good thing. The EZ-G device prototype uses innovative sensors to monitor pressure, temperature, conductivity, and heart rate to determine what enhances users' gratification. It then leverages artificial intelligence to transmit and receive data from those sensors related to conditions of the user's organs, including pressure variations due to muscle contraction. That's not all; the EZ-G prototype includes a Bluetooth component for controlling the device via an app installed on a smartphone or other portable device that collects user information about preferences to generate custom programs that are uploaded to the secured cloud, with the combined technology and product functionality supporting a positive user experience.
But know this: BCAN is more than just focused on user experience. They want to increase shareholder value, too. Targeting a multi-billion-dollar sensual wellness opportunity could lead to achieving that goal. That pathway is being paved by its device leveraging AI and machine learning algorithms to control its operational parameters based on the user's physiological data. It also records real-time user experience monitoring through integrated sensors, with its patent application covering claims that use AI to store user preference data, allowing it to learn general and current operation preferences. By collecting data on responses to different operation parameters, the power of AI streamlines its operation to provide a personalized and optimized experience for each user. Notably, the applications can benefit users outside of medical treatment.
Milestones reached support various interests. Notably, BCAN's groundbreaking EZ-G device could revolutionize specific uses of innovative sensors to treat multiple health and wellness conditions by delivering low concentrations of CBD oils, including hemp seed oil and other natural oils, to address specific women's health issues. Supporting broader use applications, BCAN conducted comprehensive experiments evaluating the functionality and performance of the integrated sensors, which detect indicators such as temperature, heart rate, and contractions.
That work led to the development of its capacitive sensor, which has demonstrated its ability to accurately detect the presence or absence of liquid, with the means to regulate the flow of oil or lubricating fluid during operation. These milestones could become catalysts, considering they position BCAN closer to initiating human trials involving focus groups across different age groups.
A Sum Of Its Parts Consideration
Still, that would represent just one value driver. To appraise BCAN properly, investors need to take a sum of its parts approach, including the many value drivers already in play. Combining those, including target market size, product innovation, and IP strength, the valuation disconnect between BCAN's share price and intrinsic and inherent potential is vast. That's not entirely bad news; it presents opportunities at prices many would have thought were extinct. Ironically, a capital raise that made BCAN appreciably stronger resulted in a decline in share price.
Thus, a wise and timely consideration may be taking advantage of a lower share price in a company intent on changing a sector, not contributing to the millions of products saturating the markets. Remember, BCAN IP-protected technology, uniquely fueled by AI, could be a game-changer for millions and, if so, would do more than satisfy clients; it would likely increase shareholder value significantly. Considering the connected devices market in the sensual wellness sector already presents a $9 billion opportunity, that's not an overly aggressive presumption.
In fact, factoring the billions in play from its product focus, the most aggressive revenue-generating expectations supporting higher valuations could prove conservative.
Disclaimers: Shore Thing Media, LLC. (STM, Llc.) is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. STM, LLC has been compensated by TD Media on behalf of BYND Cannasoft Enterprises, Inc..up to four-thousand-dollars cash via wire transfer to produce and syndicate content for BYND Cannasoft Enterprises, Inc. for a period of two weeks ending on 08/06/23. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Company Name: STM, LLC.
Contact Person: Michael Thomas
Country: United States